Patient cohort for the MS discovery studya | Patient cohort for validation study | ||||
---|---|---|---|---|---|
Recipient | RIC (n = 6) | Non-RIC (n = 6) | Recipient | RIC, n = 72 | Non-RIC, n = 74 |
Gender | Gender | ||||
Male | 5 | 5 | Male | 46 (64%) | 44 (59%) |
Female | 1 | 1 | Female | 26 (36%) | 30 (51%) |
Age, median (range) | 52.2 (43.6–60.5) | 48.0 (30.1–70.3) | Age, median (range) | 57.3 (49.7–64.8) | 60.8 (49.4–65.9) |
Dialysis mode | Dialysis mode | ||||
Pre-emptive | 3 | 4 | Preemptive | 13 (18%) | 15 (20%) |
HD | 2 | 1 | HD | 40 (56%) | 42 (57%) |
PD | 1 | 1 | PD | 18 (25%) | 16 (22%) |
HD + PD | 1 (1%) | 1 (1%) | |||
Number of transplant | Number of transplant | ||||
First | 6 | 6 | First | 63 (88%) | 65 (88%) |
Retransplant | 0 | 0 | Retransplant | 9 (13%) | 9 (12%) |
Original renal disease | Original renal disease | ||||
Glomerulopathy | 2 | 1 | Glomerulopathy | 20 (28%) | 15 (20%) |
ADPKD | 2 | 2 | ADPKD | 15 (21%) | 15 (20%) |
Diabetes mellitus | 1 | 1 | Diabetes mellitus | 8 (11%) | 8 (11%) |
Vascular/hypertension | 0 | 1 | Vascular/hypertension | 7 (10%) | 9 (12%) |
Reflux/obstructive | 0 | 0 | Reflux/obstructive | 3 (4%) | 2 (3%) |
Other | 0 | 1 | Other | 6 (8%) | 7 (9%) |
Unknown | 1 | 0 | Unknown | 13 (18%) | 18 (24%) |
Comorbidity | Comorbidity | ||||
Diabetes mellitus | 1 | 1 | Diabetes mellitus | 12 (17%) | 14 (19%) |
Hypertension | 5 | 5 | Hypertension | 62 (86%) | 69 (93%) |
Total HLA-A, D, DR mismatches | Total HLA-A, B, DR mismatches | ||||
0 | 0 | 0 | 0 | 3 (4%) | 6 (8%) |
1–2 | 0 | 0 | 1–2 | 15 (21%) | 18 (24%) |
3–4 | 5 | 6 | 3–4 | 47 (65%) | 35 (47%) |
5–6 | 1 | 0 | 5–6 | 7 (10%) | 15 (20%) |
Immunosuppression at discharge | Immunosuppression at discharge | ||||
Tacrolimus | 6 | 6 | Tacrolimus | 63 (88%) | 72 (97%) |
Mycophenolate mofetil | 6 | 6 | Mycophenolate mofetil | 70 (97%) | 74 (100%) |
Corticosteroids | 6 | 6 | Corticosteroids | 66 (92%) | 72 (97%) |
Cyclosporine | 7 (10%) | 2 (3%) | |||
None (graft loss) | 2 |
Patient cohort for the MS discovery studya | Patient cohort for validation study | ||||
---|---|---|---|---|---|
Donor | RIC (n = 6) | Non-RIC (n = 6) | Donor | RIC, n = 72 | Non-RIC, n = 74 |
Gender | Gender | ||||
Male | 4 | 4 | Male n (%) | 39 (54%) | 41 (55%) |
Female | 2 | 2 | Female n (%) | 33 (46%) | 33 (45%) |
Age, median (range) | 61.5 (55–72) | 61.5 (55–72) | Age, median (range) | 58.5 (50.5–65.5) | 56.5 (49–63) |
Paired kidneys | 6 | 6 | Paired kidneys | 28 (39%) | 28 (38%) |
Single kidneys | 44 (61%) | 46 (62%) | |||
DBD | 6 | 6 | DBD | 67 (93%) | 69 (93%) |
DCD | 5 (7%) | 5 (7%) | |||
Cause of death | Cause of death, DBD (n = 67 and 69) | ||||
Cerebrovascular insult | 5 | 5 | Cerebrovascular insult | 42 (63%) | 43 (62%) |
Cerebral anoxia | 15 (22%) | 17 (25%) | |||
Trauma | 1 | 1 | Trauma | 9 (13%) | 9 (13%) |
Benign cerebral neoplasm | 1 (1%) | 0 | |||
Cause of death, DCD (n = 5 and 5) | |||||
Cerebrovascular insult | 2 | 2 | |||
Cardiac disease | 1 | 2 | |||
Trauma | 0 | 1 | |||
Other | 2 | 0 | |||
Preservation solution | Preservation solutions | ||||
Custodiol | 5 | 5 | Custodiol | 56 (78%) | 52 (70%) |
UW | 1 | 1 | UW | 15 /21%) | 20 (27%) |
Other | 1 (1%) | 2 (3%) | |||
Warm ischemia time DCD, min | 20 (15–25) | 18 (14–25) | |||
Cold ischemia time (h) Median (range) | 12.3 (5.5–26.2) | 13.5 (8.4–21.0) | Cold ischemia time (h) DBD + DCD | ||
n > 24 h | 13.4 (3.8) | 13.9 (4.9) | |||
Missing data | 1 | 4 | |||
1 | 1 | ||||
Total surgery time (h) Median (range) | 2.1 (1.7–2.3) | 2.3 (1.3–2.6) | Total surgery time (h) Median (range) | 2.4 (2.0–2.8) | 2.5 (2.0–3.0) |
Missing data | 1 | 0 | |||
Remuzzi score, median (range) | Remuzzi score, median (range) | ||||
All biopsies | 2.5 (1–7) n = 6 | 3.5 (2–6) n = 6 | All biopsies (n = 61 and 63) | 2 (1–3) | 2 (1–4) |
6 glom | 2.5 (1–7) n = 6 | 3.5 (2–6) n = 6 | 6 glom (n = 56 and 55)b | 2 (1–3) | 2 (1–4) |
10 glom | 3 (2–4) n = 3 | 3.5 (2–4) n = 4 | 10 glom (n = 41 and 42)b | 2 (1–3) | 2 (1–4) |
Missing datac | 11 (15%) | 11 (15%) |